Incyte begins Phase II REACH-1 trial of ruxolitinib combined with corticosteroids to treat GVHD

US-based biopharmaceutical company Incyte has commenced its Phase II REACH-1 pivotal trial of ruxolitinib (Jakafi) combined with corticosteroids to treat steroid-refractory acute graft-versus-host disease (GVHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news